Acadia Pharmaceuticals
ACAD
276 hedge funds and large institutions have $4.99B invested in Acadia Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 60 funds opening new positions, 104 increasing their positions, 70 reducing their positions, and 29 closing their positions.
107% more first-time investments, than exits
New positions opened: 60 | Existing positions closed: 29
54% more capital invested
Capital invested by funds: $3.25B → $4.99B (+$1.74B)
49% more repeat investments, than reductions
Existing positions increased: 104 | Existing positions reduced: 70
29% more funds holding in top 10
Funds holding in top 10: 7 → 9 (+2)
11% more funds holding
Funds holding: 248 → 276 (+28)
1.86% more ownership
Funds ownership: 95.3% → 97.16% (+1.9%)
10% less call options, than puts
Call options by funds: $29.2M | Put options by funds: $32.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$33M |
| 2 |
State Street
Boston,
Massachusetts
|
+$29.9M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$22.9M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$19.3M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$15.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$31.5M |
| 2 |
D.E. Shaw & Co
New York
|
-$24.7M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$19.6M |
| 4 |
HRCM
Hood River Capital Management
Palm Beach Gardens,
Florida
|
-$18.3M |
| 5 |
Millennium Management
New York
|
-$15.5M |
ACAD Hedge Fund Activity: Q4 2023 in Review
276 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q4 2023, worth a combined $4.99B — up 54% from $3.25B a quarter earlier.
Buyers outnumbered sellers: 60 funds opened new ACAD positions and 29 closed out — a net gain of 31 holders — while 104 added to existing stakes and 70 trimmed.
The largest buyer was BlackRock, adding an estimated $33M. The largest seller was Jacobs Levy Equity Management, cutting an estimated $31.5M.
- 276 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q4 2023, up from 248 in Q3 2023.
- Funds reported $4.99B of Acadia Pharmaceuticals stock for Q4 2023, up 54% quarter-over-quarter.
- 60 funds opened new Acadia Pharmaceuticals positions in Q4 2023 and 29 closed out, a net change of +31 holders.
- The largest Acadia Pharmaceuticals buyer in Q4 2023 was BlackRock, an estimated $33M added.
- The largest Acadia Pharmaceuticals seller in Q4 2023 was Jacobs Levy Equity Management, an estimated $31.5M sold.
Based on aggregated 13F filings for Q4 2023.